Stock PHIO PHIO PHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up

Financials Phio Pharmaceuticals

Equities

PHIO

US71880W4024

Delayed Nasdaq
Other stock markets
 01:30:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
0.5808 USD -4.80% Intraday chart for Phio Pharmaceuticals -17.05% -23.58%
Jul. 02 Phio Pharmaceuticals Board Approves 1-For-9 Reverse Stock Split MT
May. 28 Phio Pharmaceuticals Corp. Announces Positive Recommendation from Safety Monitoring Committee of Phase 1b Clinical Study of Phio's Lead Compound PH-762 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 6.296 15.55 13.53 5.084 1.857 2.667 -
Enterprise Value (EV) 1 6.296 15.55 13.53 5.084 1.857 2.667 2.667
P/E ratio -0.49 x -1.4 x -0.96 x -0.44 x -0.15 x -0.32 x 0.15 x
Yield - - - - - - -
Capitalization / Revenue 300 x - - - - - 0.04 x
EV / Revenue 300 x - - - - - 0.04 x
EV / EBITDA - - - - - - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 55.8 482 1,128 1,139 2,443 4,592 -
Reference price 2 112.9 32.28 12.00 4.464 0.7600 0.5808 0.5808
Announcement Date 3/26/20 3/25/21 3/22/22 3/22/23 4/1/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 0.021 - - - - - 75
EBITDA - - - - - - -
EBIT 1 -8.987 -8.793 -13.51 -11.46 -10.82 -9.6 62.8
Operating Margin -42,795.24% - - - - - 83.73%
Earnings before Tax (EBT) 1 -8.908 -8.794 -13.29 -11.48 -10.83 -9.6 62.8
Net income 1 -8.908 -8.794 -13.29 -11.48 -10.83 -9.6 47.7
Net margin -42,419.05% - - - - - 63.6%
EPS 2 -232.0 -23.04 -12.48 -10.10 -5.200 -1.820 3.780
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/26/20 3/25/21 3/22/22 3/22/23 4/1/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - -
EBITDA - - - - - - - - - - - -
EBIT 1 -3.45 -2.64 -2.521 -3.571 -2.73 - -2.776 -1.899 - -2.3 -2.5 -2.6
Operating Margin - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -3.451 -2.642 -2.531 -3.576 -2.731 - -2.78 -1.895 - -2.3 -2.5 -2.6
Net income 1 -3.451 -2.642 -2.531 -3.576 -2.731 -2.549 -2.78 -1.895 -2.154 -2.3 -2.5 -2.6
Net margin - - - - - - - - - - - -
EPS 2 -3.120 -2.280 -2.280 -3.120 -2.420 -1.470 -1.140 -0.1700 -0.4700 -0.5100 -0.4600 -0.4000
Dividend per Share - - - - - - - - - - - -
Announcement Date 3/22/22 5/12/22 8/11/22 11/10/22 3/22/23 8/10/23 11/9/23 4/1/24 5/9/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 3/26/20 3/25/21 3/22/22 3/22/23 4/1/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.5808 USD
Average target price
4 USD
Spread / Average Target
+588.71%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. Financials Phio Pharmaceuticals